Hi Whitta,
From what I understand they'd prob wait a bit longer (I think originally stating Q3 or so before OA SAS pay for use program start) so as to fully recruit for all trials as there will be an Aussie component for the main trial for example). Intention is not to 'rob' potential candidates for the required trial numbers.
Trials are priority.
Just my thoughts.
Ann: Paradigm doses first participant in Synovial Fluid Trial, page-13
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.0¢ |
Change
-0.015(6.98%) |
Mkt cap ! $70.04M | |||
| Open | High | Low | Value | Volume |
| 21.0¢ | 21.0¢ | 20.0¢ | $201.6K | 994.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 429247 | 20.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.0¢ | 13806 | 2 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| PAR (ASX) Chart |